SI-BONE, Inc. (NASDAQ:SIBN) Receives Consensus Recommendation of “Buy” From Brokerages

 In Uncategorized

SI-BONE, Inc. (NASDAQ:SIBNGet Rating) has been assigned an average rating of “Buy” from the ten brokerages that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $32.63.

A number of brokerages recently issued reports on SIBN. Cantor Fitzgerald began coverage on SI-BONE in a research note on Thursday, April 7th. They set an “overweight” rating and a $34.00 price target for the company. Canaccord Genuity Group decreased their price target on SI-BONE from $32.00 to $25.00 in a research note on Tuesday, May 10th. Morgan Stanley decreased their price target on SI-BONE from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Tuesday, March 1st. Finally, Zacks Investment Research lowered SI-BONE from a “buy” rating to a “sell” rating in a research note on Friday, May 13th.

In other news, Director Jeffrey W. Dunn sold 1,474 shares of the business’s stock in a transaction on Monday, April 18th. The stock was sold at an average price of $19.92, for a total value of $29,362.08. Following the completion of the transaction, the director now directly owns 152,285 shares of the company’s stock, valued at approximately $3,033,517.20. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Michael A. Pisetsky sold 3,466 shares of the business’s stock in a transaction on Monday, May 16th. The stock was sold at an average price of $12.58, for a total value of $43,602.28. Following the completion of the transaction, the senior vice president now directly owns 123,581 shares of the company’s stock, valued at $1,554,648.98. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 25,856 shares of company stock valued at $342,884. 7.00% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA grew its stake in SI-BONE by 169.6% during the 1st quarter. BNP Paribas Arbitrage SA now owns 19,244 shares of the company’s stock worth $435,000 after buying an additional 12,105 shares during the last quarter. Penn Capital Management Company LLC grew its stake in SI-BONE by 60.8% during the 1st quarter. Penn Capital Management Company LLC now owns 460,030 shares of the company’s stock worth $10,087,000 after buying an additional 174,024 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in SI-BONE by 20.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 66,386 shares of the company’s stock worth $1,500,000 after buying an additional 11,234 shares during the last quarter. PDT Partners LLC purchased a new position in SI-BONE during the 1st quarter worth $777,000. Finally, Brinker Capital Investments LLC purchased a new position in SI-BONE during the 1st quarter worth $279,000. Hedge funds and other institutional investors own 99.36% of the company’s stock.

Shares of SI-BONE stock opened at $13.88 on Tuesday. The stock has a market cap of $470.31 million, a price-to-earnings ratio of -7.50 and a beta of 1.40. The company has a debt-to-equity ratio of 0.29, a quick ratio of 9.48 and a current ratio of 10.44. The stock has a 50 day moving average price of $19.07 and a 200-day moving average price of $20.23. SI-BONE has a one year low of $11.89 and a one year high of $34.38.

SI-BONE (NASDAQ:SIBNGet Rating) last announced its earnings results on Monday, May 9th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09). SI-BONE had a negative return on equity of 44.52% and a negative net margin of 67.00%. During the same period in the previous year, the firm posted ($0.37) earnings per share. Sell-side analysts predict that SI-BONE will post -1.84 earnings per share for the current fiscal year.

About SI-BONE (Get Rating)

SI-BONE, Inc, a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures.

Featured Articles

Analyst Recommendations for SI-BONE (NASDAQ:SIBN)

DefenseWorld source|articles

Favorite 0

Start typing and press Enter to search